Fero Industries, Inc. Announces Interim Chief Financial Officer

       Fero Industries, Inc. Announces Interim Chief Financial Officer

PR Newswire

CALGARY, Alberta, Jan. 22, 2013

CALGARY, Alberta, Jan. 22, 2013 /PRNewswire/ -- Fero Industries, Inc. (OTC:
FROI), the exclusive producer, marketer & distributor of Sucanon®, an oral
type-2 Diabetes treatment, announced today that the company has hired Barry
Hall, through his consulting company Carlaris LV Inc., as Interim CFO. Mr.
Hall is the former CFO of EarthLink and brings extensive experience in
accounting, corporate governance and strategic planning to the company.

"Barry's high level of experience is exactly what we need to move Fero
Industries forward," commented Luis Lopez, Fero Industries Chief Executive
Officer. "We are continuously working to position the company favorably as a
public entity, and we understand that it is essential to prepare for an
eventual audit which will lead to up-listing on the exchange. Barry's first
project for Fero will be to file our unaudited financials on OTC Markets, and
we are excited at the progress that can be made with someone like him on our
team."

Barry Hall states, "I'm very eager to begin working with Fero and their
exceptional Type II diabetes drug, Sucanon®. I believe strongly in the company
and their mission, and am looking forward to helping them achieve their
financial objectives."

Barry Hall has over 35 years of business experience that combines a strong
financial background with a deep knowledge and practice of general management.
He has been a CEO, COO and CFO for a variety of publicly and privately traded
Internet, High Technology, and Telecommunications companies. He was the
Founder and CFO of Thwapr Inc. a mobile video technology company; the Chief
Financial Officer of EarthLink, Inc. who led its IPO; Chairman and CEO of
CalAmp Corp, where he developed and directed the business strategy and
marketing plan that turned this publicly held manufacturer of satellite
television and wireless cable amplifiers from near bankruptcy, to the #10
small corporation in the United States (Business Week).

Barry holds an MBA and a BA in Mathematics, and served in the United States
Marine Corps as a Tank Platoon Commander, advancing to the rank of Captain
prior to his discharge.

About Sucanon^®

Sucanon^® is one of only three approved drugs in the multi-billion dollar
market for a class of diabetic medications called "insulin sensitizers".
Pre-clinical and clinical studies show that Sucanon^® and other insulin
sensitizers lower a patient's blood sugar by increasing the muscle, fat and
liver's sensitivity to the body's own naturally produced insulin. Sucanon^®
has been approved for prescription sale in China and Peru. Sucanon^® is also
approved as an OTC treatment for Type-II diabetes by regulatory authorities in
Mexico, and is distributed there under an exclusive agreement with Merck S.A.
de C.V.

For further information regarding Sucanon^®, please visit the Fero Industries
Inc. website at www.feroindustries.com.

About Fero Industries Inc.

Fero Industries, Inc. (OTC: FROI) is focused on diabetes prevention and
treatments. The Company holds the intellectual property and all exclusive
world-wide rights related to the production, marketing, and distribution of
Sucanon^®, an oral treatment for Type-II diabetes. Sucanon^® is a member of a
class of diabetic medications called insulin sensitizers. Insulin sensitizers
lower blood sugar by increasing the muscle, fat and liver's sensitivity to
insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs
that help return the blood sugar to the normal range without the risk of low
blood sugars. Fero's strategy is to increase awareness, acceptance, and
distribution of Sucanon^® globally.

For investor relations contact:

Michael Irving
Paramount Advisors, LLC
(407) 878-5462

SOURCE Fero Industries, Inc.

Website: http://www.feroindustries.com
 
Press spacebar to pause and continue. Press esc to stop.